Hi all,
Recently bought into Fractyl Health, which is basically trying to make a “gut reset” treatment for people who lose weight on Ozempic/Wegovy-type drugs and then gain it back after stopping. Their main treatment, Revita, is a scope procedure that burns part of the upper intestine lining so the body responds to insulin and metabolism differently, with the goal of helping people keep weight off without needing GLP-1 shots forever.
The stock recently dropped because investors were hoping Revita would nearly eliminate weight regain after stopping GLP-1s, but the data showed **70\~% reduction in regain vs placebo.** This is good, but not the massive outcome some people had priced in. Since this was still midpoint trial data and not final pivotal results, the market started pricing in more uncertainty around adoption, timelines, and future dilution.
**Valuation**
However, I do think it's underpriced. If we look at the valuations the stock is still trading at bear case level. Even if this goes to back base case levels, there's quite some upside:
* **Bear case:** Weak or inconsistent pivotal data, unclear positioning -> \~$50M-$200M market cap -> \~$0.30-$1/share
* **Base case:** Works in a subset, slower adoption, niche use -> \~$400M-$800M market cap -> roughly \~$2-$4/share
* **Bull case:** Strong pivotal + clear role post-GLP-1 + adoption builds -> $1.5B+ market cap -> $7-$12+/share
**Upcoming catalysts**
Revita:
* Q2: 1-year durability data (REVEAL-1) Helpful, but not a thesis changer unless it’s unusually strong
* Q3: additional REMAIN-1 updates Likely more follow-up and expanded data, not the final word
* Late 2026 / early 2027: pivotal REMAIN-1 topline This is the real event. Everything hinges on this
* After that: possible De Novo submission, depending on data quality
Rejuva: (early stage and shouldn't drive valuation yet, but worth mentioning)
* Q2: CTA feedback
* H2: potential first-in-human dosing
They currently have about $85.6M cash on hand (January 2026), which should be enough to get through the upcoming Revita data and the early Rejuva milestones. If Revita keeps progressing though, they’ll probably still need to raise more money later for bigger studies and commercialization.
The stock has also started recovering a bit over the last month, which could mean sentiment is slowly improving again after the big selloff.
That said, this is still a risky biotech penny stock, so I only allocated a small portion of my portfolio to it. To me it looks more like a situation where the market is already pricing in a lot of failure, while there’s still a decent amount of upside left if the pivotal data ends up being good.
Would love to hear some counterarguments!